Sun Pharmaceutical Industries Ltd SUNPHARMA.NS · INR
Pharmaceuticals · NSE · 🇮🇳 India
Nifty 50
1,904.50
+2.39%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sun Pharmaceutical Industries Ltd
Its shares trade on NSE under the ticker SUNPHARMA.NS. It has been listed since 1 January 1994. It is a member of the Nifty 50. In the fiscal year to 31 March 2026, it reported revenue of ₹582.20bn and net income of ₹114.79bn. At that date it held total assets of ₹1.09trn and shareholders' equity of ₹835.70bn.
Sun Pharmaceutical Industries Ltd. engages in manufacturing, developing, and marketing of pharmaceuticals products. The company is headquartered in Mumbai, Maharashtra. The firm is engaged in the business of manufacturing, developing and marketing a range of generic formulations. The company produces a portfolio of generic and specialty medicines targeting a spectrum of chronic and acute treatments. The Company’s product portfolio includes generics, branded generics, specialty, over the counter (OTC)/consumer healthcare products, anti-retrovirals (ARVs), active pharmaceutical ingredients (APIs) and intermediates. Its OTC brands includes Faringosept , Revital, and Volini. The firm offers its products in variety of dosage forms, such as tablets, capsules, sprays, injectables, inhalers, ointments, creams and liquids. Its portfolio of specialty products, branded generics are available across 100 countries. The firm operates manufacturing sites across 6 continents.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 1 Jan 1994
- Employees
- 38,000
- Website
- sunpharma.com ↗
Leadership
Pay as last reported
- Mr. Dilip ShanghviExecutive Chairman of the Board, since 2025₹64.8m
- Ms. Jayashree SatagopanChief Financial Officer
- Mr. Aalok ShanghviWhole-time Director and Chief Operating Officer₹75.8m
- Mr. Anoop DeshpandeCompliance Officer, Company Secretary
- Mr. Kirti GanorkarManaging Director
- Ms. Vidhi ShanghviWhole-Time Director, since 2025
- Dr. Pawan GoenkaLead Non-Executive Independent Director₹10.8m
- Ms. Rama BijapurkarNon-Executive Independent Director₹6.8m
- Shri. Gautam DoshiNon-Executive Independent Director₹9.8m
- Mr. Rolf HoffmannNon-Executive Independent Director₹6.6m
- Dr. Abhishek SharmaInvestor Relations Officer, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 79
- Environment
- 71
- Social
- 85
- Governance
- 79
- Direct emissions (scope 1)
- 45,606.09 t
- Energy emissions (scope 2)
- 323,237.43 t
- Value chain emissions (scope 3)
- 379,788.3 t
- Women in the workforce
- 18.1%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong product portfolio: Sun Pharmaceutical Industries Ltd has a diverse range of medications and healthcare products, catering to various therapeutic segments. This enables the company to effectively serve a wide customer base and maintain a competitive edge in the market.
- Established brand reputation: Sun Pharma, as it is commonly known, has been in the pharmaceutical industry for several decades and has earned a strong reputation for its quality medications and successful track record. This brand recognition gives the company an advantage when entering new markets or launching new products.
- Robust manufacturing capabilities: The company owns several state-of-the-art manufacturing facilities that adhere to stringent quality standards. This enables Sun Pharma to produce high-quality medications in large volumes, meeting the growing demand both domestically and internationally.
Weaknesses
- Dependence on a few key markets: Although Sun Pharma has a global presence, the company heavily relies on a limited number of markets for the majority of its revenue. Any adverse changes in these markets, such as unfavorable regulations or economic downturns, can significantly impact Sun Pharma's business and financial performance.
- Product recalls and regulatory issues: In the past, Sun Pharma has faced some product recalls and regulatory compliance issues, which resulted in reputational damage and financial losses. These incidents highlight a weakness in the company's quality control and regulatory processes that need to be addressed and improved.
Opportunities
- Growing global pharmaceutical market: The global pharmaceutical market is expanding rapidly due to the increasing prevalence of diseases and the aging population. Sun Pharma can capitalize on this opportunity by expanding its product line, entering new markets, and forming strategic alliances to enhance its market share and profitability.
- Investments in research and development: By investing in research and development (R&D), Sun Pharma can develop innovative medications and formulations, ensuring a competitive advantage in the market. The company can also focus on developing generic versions of popular drugs or other niche therapeutic areas to tap into untapped markets.
Threats
- Intense competition: The pharmaceutical industry is highly competitive, with numerous global and local players vying for market share. Sun Pharma faces competition from both established pharmaceutical companies and emerging generics manufacturers. This increased competition can affect pricing and profitability.
- Stringent regulations and pricing pressures: Governments around the world are imposing stricter regulations on pharmaceutical companies, focusing on safety, efficacy, and pricing. Compliance with these regulations can be challenging and costly for Sun Pharma, potentially leading to decreased profit margins. Additionally, pricing pressures can negatively impact the company's revenue and profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.